|会社名||Becton Dickinson_Co （BDX ベクトン・ディッキンソン）|
|業種||医療機器_医療用品_ディストリビュ―タ― 医療関連（Health Care）|
|概要||事業概要 ベクトン・ディッキンソン（Becton Dickinson and Company）は医療用品、装置、実験装置および診断用製品を開発・製造・販売するグローバルな医療技術会社である。同社はBD医療事業とBD生命科学事業を運営する。BD医療事業は、各種のセッティングでヘルスケア提供を改善するために使用される一連の医療技術と医療機器を製造する。同事業は、糖尿病ケア、投薬および手続きソリューション、投薬管理ソリューション、医薬品システムなど、各ビジネスユニットで構成される。BD生命科学事業は感染症、医療関連感染症、およびがんを検出するために、診断標本、器具および試薬システムを安全に収集・輸送するための製品を提供する。同事業は、診断システム、バイオサイエンスなど、各ビジネスユニットが含まれる。 ベクトン・ディッキンソンは医療機器、検査室用器材、抗体、試薬、診断用製品を製造する。事業は3部門で構成。メディカル部門は注射針、静脈内カテ―テル、薬剤充填済みキット製品などを提供。ダイアグノスティクス部門は病院向けに採血管・キット、子宮頸がん診断用細胞検診製品など、またバイオサイエンス部門は乾細胞解析・分離装置などを製造する。 BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.|
|代表者氏名||Vincent A. Forlenza|
|代表者役職名||Chairman of the Board Chief Executive Officer|
|決算概要||決算概要 BRIEF: For the three months ended 31 December 2018 Becton Dickinson and Co revenues increased 35% to $4.16B. Net income applicable to common stockholders excluding extraordinary items increased from $96M to $613M. Revenues reflect Interventional segment increase from $183M to $970M Medical segment increase of 15% to $2.14B United States segment increase of 44% to $2.39B International segment increase of 25% to $1.77B.|
Watch this stock’s price performance: Becton Dickinson and Company (NYSE:BDX) 2022/08/01 17:12:00 US Post News
Becton Dickinson and Company (BDX)’s stock is trading at $244.14 at the moment marking a fall of -0.07% from the last session close. As of this writing, shares are priced at -11.95% less than their 52-week high of $277.29, and 6.50% over their 52-week low of $229.24. Based on the past 30-day period, the stock […]
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $8,800 Today 2022/07/28 16:00:23 Benzinga
Becton, Dickinson (NYSE: BDX ) has outperformed the market over the past 20 years by 3.42% on an annualized basis producing an average annual return of 11.36%. Currently, Becton, Dickinson has a market capitalization of $68.64 billion. Buying $1000 In BDX: If … Full story available on Benzinga.com
Becton, Dickinson acquires MedKeeper to offer cloud-based, connected pharmacy software 2022/07/28 11:35:02 Seeking Alpha
Becton, Dickinson (BDX) acquired MedKeeper, a provider of modern, cloud-based pharmacy management applications, for providing customers with flexibility and capabilities in meeting…
Becton, Dickinson: Acquisitions Underwhelming (NYSE:BDX) 2022/07/27 22:49:52 Seeking Alpha
We believe the healthcare sector''s strong growth momentum with average revenue growth of 3.8% QoQ suggests a positive outlook with the equipment industry forecasted at a market CAGR of 5.5%.
Becton, Dickinson declares $0.87 dividend 2022/07/26 20:19:37 Seeking Alpha
Becton, Dickinson (BDX) declares $0.87/share quarterly dividend, in line with previous.
Analyzing Becton, Dickinson''s Short Interest 2022/06/10 13:18:30 Benzinga
Becton, Dickinson''s (NYSE: BDX ) short percent of float has risen 11.94% since its last report. The company recently reported that it has 4.25 million shares sold short , which is 1.5% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.4 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price … Full story available on Benzinga.com
Becton, Dickinson partners with CerTest Biotec for monkeypox test 2022/06/08 11:10:53 Seeking Alpha
Becton, Dickinson and Company (BDX) and CerTest Biotec, a European diagnostic device maker, announced a collaboration on Wednesday to develop a molecular diagnostic test for the…
Becton Dickinson Rises on Plans to Enter Automation Market 2022/06/07 15:04:49 TipRanks
Medical technology company Becton Dickinson and Co. (NYSE: BDX) has signed an agreement to acquire a pharmacy automation solutions provider, Parata Systems, for $1.525 billion in cash. North Carolina-based Parata’s offerings include pharmacy workflow solutions, high-speed robotic dispensing technologies and medication adherence packaging. For the year ended March 31, 2022, the company recorded revenues of around $220 million. Tom Polen, the Chairman, CEO and President of Becton Dickinson (BD), said, “Parata expands BD''s solutions to a new area of the high-growth pharmacy automation space. Parata has a highly attractive financial profile and compelling value proposition that meets all of our rigorous investment criteria on growth, profitability and returns.
Becton Dickinson buys into pharmacy automation with $1.5B Parata acquisition - MedCity News 2022/06/06 21:24:24 MedCity News
Becton Dickinson is getting into pharmacies with a more than $1.5 billion acquisition of Parata Systems, maker of robotics technologies that automate pharmacy tasks. The deal comes two months after BD completed the spinoff of its diabetes business as a separate, publicly traded company.
Becton Dickinson Buying Parata Systems - Read Why 2022/06/06 15:16:47 Benzinga
Becton Dickinson and Co (NYSE: BDX ) will acquire Parata Systems from Frazier Healthcare Partners for $1.525 billion . Parata offers a portfolio of pharmacy automation solutions to reduce costs, enhance patient safety and improve the patient experience. Significant macro trends such as clinician shortages, wage inflation, centralization of pharmacy services, and increased clinical demands … Full story available on Benzinga.com
Aaron Wealth Advisors Buys Vanguard Russell 1000 Growth Index Fund, Vanguard Russell 1000 Value ... 2021/07/29 20:38:20 GuruFocus
Related Stocks: VONG , VONV , IEFA , IEMG , GUNR , IGF , SPG , ESML , EPD , RETA , EBAY , ISRG , BDX , GWRE , KDP , AIG , ESGU , BABA ,
BD begins remediation following BD Alaris system software recall 2021/07/29 12:26:26 Drug Delivery Business
BD (NYSE:BDX) announced today that it will begin remediation for a 2020 recall of its Alaris infusion system. Franklin Lakes, N.J.-based BDs remediation for the Feb. 4, 2020, recall of the BD Alaris system will begin through a new version of software after a voluntary recall alerted customers to a number of areas in which  The post BD begins remediation following BD Alaris system software recall appeared first on Drug Delivery Business .
BD to Begin Remediation for BD Alaris System Software 2021/07/29 10:50:00 Becton Dickinson and Co
FRANKLIN LAKES, N.J. , July 29, 2021 /PRNewswire/ -- BD ( Becton, Dickinson and Company ) (NYSE: BDX), a leading global medical technology company, today announced the company will begin remediation for the February 4, 2020 BD Alaris System 1 recall through a new version of software.
Palouse Capital Management, Inc. Buys Apple Inc, Telefonaktiebolaget L M Ericsson, Xilinx Inc, ... 2021/07/28 20:38:07 GuruFocus
Related Stocks: AAPL , T , SCHD , ERIC , XLNX , IBKR , BABA , BDX , ENS , GD , HPQ , SJM , SYKE , CATY , MTRX ,
Blood Transfusion Devices Market is Projected to Showcase Significant Growth up to 2027 Covid-19 Analysis | Cerus, Becton Dickinson 2021/07/28 09:27:06 OpenPR
To make market monitoring and sale services easier, this Blood Transfusion Devices market Report concentrates on key market segments. It will also help you attract different types of customers by putting forth important tactics. It also reveals the competitors'' strengths